The Company announced that it embarked on a new initiative to define its two distinct business pillars, BioStem Technologies and BioStem Life Sciences. The new strategic focus of BioStem Technologies is to identify, develop and market the life changing regenerative biologics, formally spearheaded by BioStem Life Sciences. This includes an all new biologic therapeutic pipeline focused on Acute Respiratory Distress Syndrome (ARDS) and Osteoarthritis (OA). BioStem Technologies will also assume the sales and distribution of the RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC brands.
This new website provides detailed information about the capabilities of the company as a Contract Development and Manufacturing Organization (CDMO), as well as aligning with the company’s brand identity. Since introducing its Contract Development and Manufacturing division earlier this year, BioStem Life Sciences has garnered an impressive uptick in potential partnership inquiries. The new website helps to better convey their capabilities, not just in development and production, but in Quality and Regulatory as well.
BioStem Life Sciences today announced the buildout of a brand new R&D lab. Situated in the Company's 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company's growing Contract Development and Manufacturing (CDMO) business.
BioStem Technologies, Inc. today announced its attendance at the 2020 Perinatal Stem Cell Society Conference. The event, scheduled to be held at the Leonardo Museum in Salt Lake City, Utah, on March 4-6, 2020, brings together industry leaders and academics who are developing and progressing the science of perinatal tissues and how they contain enormous, untapped life potential to help solve diseases and disorders.